新闻资讯
What should be considered when choosing a gum base for chewing gum?

2026-02-26

What should be considered when choosing a gum base for chewing gum?

The core of choosing chewing gum base is compliance and safety, taste adaptation, stable processing, and controllable cost, which directly determines product quality and market acceptance. Firstly, it must comply with national food safety standards, and the rubber based raw materials and additives must be within the allowable range of national standards such as GB 2760 and GB 1886.237. The use of non edible resins and unknown additives is prohibited. Prioritize selecting legitimate suppliers with SC production licenses and third-party testing reports to ensure compliance with standards for heavy metals, microorganisms, and solvent residues. Secondly, it is necessary to match the taste and chewing performance: the softness, hardness, initial chewiness, extensibility, and fragrance retention of different gum bases vary greatly. Need to choose based on product positioning - soft rubber base with gentle entrance, suitable for children's styles; Medium to high elasticity gum base is chewy and has good durability, suitable for adult sugar free chewing gum. Processing stability is also crucial. High quality gum base has a moderate melting point, is easy to soften, and has good compatibility with sugar powder and syrup. It is not easy to stick or break during production, and has stable molding, making it suitable for industrial continuous production. Pay attention to the temperature resistance of the adhesive base to avoid softening and deformation during storage and transportation. Also consider formula compatibility: whether it is stable with sweeteners, essence, pigments, antioxidants, etc., and whether it affects fragrance retention, color and shelf life. Finally, taking into account cost and supply capacity, we will select a rubber base manufacturer with stable quality, good batch consistency, and comprehensive after-sales technical support to ensure the safety, taste, and production efficiency of chewing gum from the source.

Learn More
What are the future trends in tablet manufacturing technology?

2026-02-26

What are the future trends in tablet manufacturing technology?

The future tablet production process will be upgraded around five directions: intelligence, continuity, personalization, greenness, and precise delivery. The core is to move from "batch standardization" to "flexible customization", balancing efficiency, quality, and safety. 1、 Intelligent Manufacturing and Digital Twin Introduce AI+IoT+big data throughout the entire process to achieve real-time parameter monitoring, adaptive control, and predictive maintenance. The key processes such as tablet pressing and coating are dynamically optimized by AI algorithms, and digital twin simulation production is used to reduce trial and error and waste. 2、 Continuous Manufacturing Popularization By replacing traditional batch production with technologies such as continuous direct pressing (CDC), materials can be processed from feeding to finished products in one go, resulting in reduced energy consumption, less loss, and higher batch consistency. It is expected that the proportion of continuous manufacturing production lines will significantly increase by 2030. 3、 3D/4D Printing and Personalized Production 3D printing can produce complex structures such as core-shell, multi-layer, and porous structures, achieving precise controlled release, multi drug integration, and dose customization. 4D printing further incorporates a time dimension, allowing tablets to be accurately released in response to environmental factors such as pH and temperature within the body. Hospitals/pharmacies can print on demand, suitable for children, the elderly, and rare disease patients. 4、 Green and low-carbon production Adopting solvent-free coating, biodegradable excipients, and recycled materials to reduce energy consumption and waste. Miniaturization and modularization of equipment, reducing clean area and operating costs. 5、 Accurate delivery and new excipients Nanocrystals and intelligent responsive excipients enhance the dissolution and bioavailability of insoluble drugs. Multi layer film and microfluidic controlled preparation achieve sequential release and targeted delivery, reducing side effects. 6、 Quality and Compliance Upgrades Process Analysis Technology (PAT) enables online full inspection, moving from "spot checks" to "zero defects". The data is fully traceable and meets global GMP and ICH standards.

Learn More
The Application of AI Technology in the Pharmaceutical Industry

2026-02-25

The Application of AI Technology in the Pharmaceutical Industry

AI technology is comprehensively empowering the pharmaceutical industry, driving its transformation toward precision and efficiency across the entire value chain—from drug discovery and development to clinical diagnosis and treatment, and health management. In the field of drug discovery, AI’s intelligent, end-to-end design approach is breaking through traditional bottlenecks. For instance, the “AI Kongming” platform provides seamless coverage from target analysis to drug-likeness optimization, significantly boosting the hit rate of candidate molecules. At the same time, AI can simulate the effects of drugs, shortening the R&D cycle and reducing costs.

Learn More
What standards must a cleanroom for capsule production meet?

2026-02-25

What standards must a cleanroom for capsule production meet?

Capsule production cleanrooms must strictly comply with pharmaceutical GMP regulations, ISO 14644, GB 50457, and other national standards, with comprehensive control over the environment, personnel, materials, and facilities. The cleanrooms are classified into four cleanliness levels: A, B, C, and D. Key processes such as capsule forming, cutting, joining, and inner packaging are generally carried out in C-level and D-level clean areas; high-risk exposure operations must be performed under an A-level laminar flow environment. Regarding environmental parameters, the pressure difference between different clean areas should not be less than 10 Pa to prevent contamination and cross-contamination; temperature should be controlled between 18–26°C, and humidity between 45%–60%, to prevent capsules from absorbing moisture, deforming, or molding. Air undergoes three-stage filtration through primary, intermediate, and high-efficiency filters to ensure that suspended particles and microorganisms meet standards. The workshop layout requires separation of personnel and material flows, with changing rooms, airlocks, and buffer zones; floors, walls, and ceilings should be smooth, seamless, and easy to clean and disinfect. Personnel must wear proper attire and undergo disinfection according to regulations, and equipment and tools must be regularly cleaned and sterilized. Meanwhile, the cleanroom must meet static and dynamic monitoring requirements, with continuous testing of suspended particles, settled bacteria, and airborne microorganisms, ensuring that the entire process complies with pharmaceutical production cleanliness requirements, thereby ensuring the safety, stability, and quality of capsules from the source.

Learn More
What qualifications are required for contract manufacturing of candy and health supplements?

2026-02-26

What qualifications are required for contract manufacturing of candy and health supplements?

Contract manufacturing of candy and health supplements requires both the client and the manufacturer to possess the corresponding qualifications. The key points are SC license, system compliance, Blue Hat registration (if applicable), and complete agreements.

Learn More
History of pill production process

2026-02-26

History of pill production process

The tablet manufacturing process has evolved from manual to automated over nearly two hundred years, with precision, efficiency, and stability at its core. Before the 1840s, medicines were mainly in pill or powder form. In 1843, the Briton Brockden invented the molding method, pressing powdered medicine into tablets using molds, laying the foundation for modern tablets. In 1872, the first tablet press was introduced, achieving mechanical compression and significantly improving efficiency and dosage accuracy. In the early 20th century, wet granulation became widespread, allowing granulation before tablet compression, which solved issues of poor powder flow and layering. After the 1950s, dry granulation and direct compression technologies matured, suitable for heat-sensitive and moisture-unstable drugs. In the 1960s, sugar coating was promoted to protect the medicine and mask bitterness; from the 1980s, film coating replaced sugar coating, being thinner, more stable, moisture-resistant, and antioxidative. In recent decades, fluidized bed granulation, high-speed tablet compression, and interconnected production lines have become widespread, achieving full-process automation and clean production. New technologies such as sustained-release, orally disintegrating, and multilayer tablets have emerged, combining with nanotechnology to improve dissolution and bioavailability. Today, tablet production has established a standardized process of pulverization — granulation — drying — tableting — coating — packaging, strictly following GMP, making it the most widely used oral dosage form worldwide.

Learn More
Why tablets can act quickly on the human body

2026-02-26

Why tablets can act quickly on the human body

The quick effectiveness of tablets lies in the combined effects of formulation design, manufacturing process, and the body's absorption mechanisms. Firstly, disintegrants are added during tablet production. These substances rapidly absorb water and swell or break apart, causing the tablet to disintegrate into fine particles in a short time, increasing the surface area in contact with bodily fluids rather than dissolving slowly as a whole. Secondly, qualified tablets must meet strict dissolution standards, ensuring that the active ingredients are released within a specified time. When drugs are made into micronized raw materials, the smaller particle size allows faster dissolution and quicker entry into bodily fluids. Once inside the body, tablets rapidly disintegrate and dissolve in the gastrointestinal tract, forming a drug solution. Small-molecule drugs can quickly pass through the gastrointestinal mucosa into the bloodstream, reaching the affected area or distributing systemically through circulation, bypassing the lengthy food digestion process and thus acting quickly. Different dosage forms can also accelerate absorption in specific ways: orally disintegrating tablets and sublingual tablets dissolve in the mouth without water, directly entering the bloodstream and avoiding first-pass metabolism in the liver, resulting in faster onset. Additionally, tablets have precise dosages and high purity, with no extra impurities to interfere, allowing the drug to act directly on the target. The manufacturing process strictly controls hardness, disintegration time, and dissolution rate to ensure each tablet releases its active ingredients stably and rapidly. It is these design features that make tablets a commonly used dosage form that acts quickly, is convenient to use, and provides accurate dosing.

Learn More
Trends in the development of health supplements in China

2026-02-25

Trends in the development of health supplements in China

China’s health-care product industry has entered a high-quality development phase characterized by both intensified competition within an existing market and simultaneous structural upgrades. While the market size continues to grow steadily, the drivers of growth are shifting toward precision and value creation. On the consumer side, there is a dual trend of broadening age demographics and increasing market segmentation. The elderly population continues to expand their demand for bone and cardiovascular health products, while Generation Z is fueling the rise of emerging needs such as liver protection, anti-aging, and emotional regulation. Meanwhile, penetration rates are rising in niche segments like nutritional supplements for children. In terms of product categories, traditional core segments are experiencing steady growth, while “medicine-food homology” and emerging functional categories are rapidly gaining momentum. Precision nutrition has become the key strategic direction. The channel landscape is being reshaped: online channels now account for over 60%, with interest-based e-commerce—driven by content-driven recommendation models—emerging as the primary growth engine. Cross-border e-commerce has become a crucial gateway for introducing new products. Product innovation focuses on upgrading dosage forms and enhancing value. Snack-like, convenient dosage forms are breaking away from the traditional “medicinal” image, and new products are achieving premium pricing through innovations in ingredients and manufacturing processes. Industry competition is shifting toward a battle of overall brand strength, presenting growth opportunities for contract manufacturers. Fine-grained operations and the development of specialized expertise are becoming the core competitive advantages for brands.

Learn More
What regulations must be strictly followed for pharmaceutical contract manufacturing?

2026-02-25

What regulations must be strictly followed for pharmaceutical contract manufacturing?

Contract manufacturing of pharmaceutical products (commissioned production) must strictly comply with regulations such as the "Drug Administration Law," the "Measures for the Supervision and Administration of Pharmaceutical Production," and the "Pharmaceutical GMP." The core requirements revolve around qualification licensing, quality responsibility, production compliance, risk management, and prohibitive requirements. Both the commissioning party (the Marketing Authorization Holder, MAH) and the contract manufacturer must obtain pharmaceutical production licenses. The contract manufacturer must also receive GMP compliance certification for the corresponding dosage form. For certain products—such as traditional Chinese medicine injections—additional age-related requirements apply to the qualifications of personnel and production records of both parties. Prior to entrusting production, the MAH must assess the contract manufacturer's capabilities in quality and risk management, and sign a commissioning agreement and a quality agreement that conform to regulatory guidelines, clearly defining the responsibilities of each party at key stages. The MAH bears overall responsibility for the quality of the drug throughout its entire lifecycle, and the contract manufacturer is prohibited from sub-contracting the work to third parties. The production process must strictly adhere to the approved registration standards and manufacturing procedures, implement GMP-compliant full-process control, and ensure that records are authentic and traceable. Material suppliers shall be reviewed and managed by the Marketing Authorization Holder (MAH). Critical equipment must undergo validation and be revalidated periodically. Before products leave the factory, they must be reviewed and released by the Qualified Person for Quality Assurance. The manufacture of active pharmaceutical ingredients, pharmaceutical preparations containing controlled substances, and other such products is prohibited from being outsourced. Any change in the manufacturing enterprise requires approval from the provincial drug regulatory authority and completion of corresponding research and verification. Both parties must establish a quality system and a change-control mechanism, and subject themselves to comprehensive regulatory oversight by the drug regulatory authority throughout the entire supply chain, thereby ensuring the safety, quality, and compliance of pharmaceutical production.

Learn More
Why is capsule production so strict?

2026-02-25

Why is capsule production so strict?

The entire capsule production process is strictly controlled, with the core focus on ensuring medication safety, preventing cross-contamination, and complying with regulatory standards, which directly affects patients' lives and health. Capsules are mostly oral medications that enter the human digestive system directly. If the production environment is unclean or the raw materials are substandard, it can easily cause allergies, infections, or even more serious health risks. Hollow capsules themselves are made from gelatin, plant fibers, and other materials, which are prone to absorbing moisture, deteriorating, and breeding microorganisms. They must be produced in temperature- and humidity-controlled cleanrooms of at least Class 100,000, with strict control over bacteria, mold, and heavy metal content. Drug production follows GMP standards. From raw material acceptance, gel preparation, dipping, drying, de-shelling, cutting, to fitting, every step has precise parameters and full records. Personnel, equipment, materials, and packaging must be managed in separate zones to prevent cross-contamination between different drugs and batches and to avoid mix-ups. Additionally, capsules must meet stringent quality indicators such as weight variation, disintegration time, and sealing integrity and undergo multiple inspections before leaving the factory. Regulatory authorities routinely conduct spot checks and on-site inspections of pharmaceutical companies, and violations can result in production stoppages, license revocation, and other severe penalties. Strict production is not an extra requirement but the baseline standard of the pharmaceutical industry. Only through standardized and regulated processes can the safety, efficacy, and stability of every capsule be ensured.

Learn More
< 1 >